Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative disorder causing disability among young individuals worldwide. There is a higher prevalence of MS in developed countries compared to other parts of the world, supporting the idea that genetic and environmental factors (or their interactions) play a role in its etiology. Early and unrestricted access to high-efficacy disease-modifying therapies in some developed countries have been shown to delay neurological damage and modify the natural disease evolution of MS. In addition, several developed countries (predominantly European countries and North America) developed national MS registry to improve the quality of care and provide valuable information for clinicians and the public. However, it is important to note that healthcare systems, approved standard treatments, and therapeutic practices may vary worldwide, while populations in developing countries are usually understudied. Therefore, more attention should be given to these people. Using real-world data from developing countries, a better understanding of disease prognosis, comparative effectiveness, long-term risks, and benefits is essential and may generate noteworthy findings.
This Research Topic aims to provide up-to-date information on MS and related diseases (including Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease) regarding demographic data, clinical manifestations, diagnostic dilemma, and disease management in developing countries.
We welcome the submission of manuscripts (Research Article, Brief Research Article, Mini-Review, and Review) focusing on, but not limited to, the following themes:
- The incidence, prevalence, quality of life, and mortality of MS and related diseases worldwide
- Genetic, lifestyle, and environmental factors of MS and related diseases worldwide
- Diagnostic dilemma of MS and related diseases in developing countries
- Serum and cerebrospinal fluid biomarkers in MS and related diseases
- Neuroimaging findings of MS and related diseases
- Prognosis and management of MS and related diseases
- Efficacy and safety profiles of disease-modifying treatments in developing countries
- Vaccination and disease-modifying treatments in developing countries
- The role of disease-modifying treatments in infection risk
- Telemedicine in MS patient care in developing countries
Multiple sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative disorder causing disability among young individuals worldwide. There is a higher prevalence of MS in developed countries compared to other parts of the world, supporting the idea that genetic and environmental factors (or their interactions) play a role in its etiology. Early and unrestricted access to high-efficacy disease-modifying therapies in some developed countries have been shown to delay neurological damage and modify the natural disease evolution of MS. In addition, several developed countries (predominantly European countries and North America) developed national MS registry to improve the quality of care and provide valuable information for clinicians and the public. However, it is important to note that healthcare systems, approved standard treatments, and therapeutic practices may vary worldwide, while populations in developing countries are usually understudied. Therefore, more attention should be given to these people. Using real-world data from developing countries, a better understanding of disease prognosis, comparative effectiveness, long-term risks, and benefits is essential and may generate noteworthy findings.
This Research Topic aims to provide up-to-date information on MS and related diseases (including Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease) regarding demographic data, clinical manifestations, diagnostic dilemma, and disease management in developing countries.
We welcome the submission of manuscripts (Research Article, Brief Research Article, Mini-Review, and Review) focusing on, but not limited to, the following themes:
- The incidence, prevalence, quality of life, and mortality of MS and related diseases worldwide
- Genetic, lifestyle, and environmental factors of MS and related diseases worldwide
- Diagnostic dilemma of MS and related diseases in developing countries
- Serum and cerebrospinal fluid biomarkers in MS and related diseases
- Neuroimaging findings of MS and related diseases
- Prognosis and management of MS and related diseases
- Efficacy and safety profiles of disease-modifying treatments in developing countries
- Vaccination and disease-modifying treatments in developing countries
- The role of disease-modifying treatments in infection risk
- Telemedicine in MS patient care in developing countries
